

Chun-Ming Tsai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3574655/publications.pdf>

Version: 2024-02-01

52
papers

6,682
citations

236925

25
h-index

206112

48
g-index

52
all docs

52
docs citations

52
times ranked

6898
citing authors

#	ARTICLE	IF	CITATIONS
1	Sequence for Surgical Resection of Primary Lung Tumor for Oligometastatic Non-small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2022, 113, 1333-1340.	1.3	1
2	Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice. <i>Current Oncology</i> , 2022, 29, 2154-2164.	2.2	16
3	Efficacy of liquid biopsy for disease monitoring and early prediction of tumor progression in EGFR mutation-positive non-small cell lung cancer. <i>PLoS ONE</i> , 2022, 17, e0267362.	2.5	6
4	Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations. <i>International Journal of Clinical Oncology</i> , 2021, 26, 841-850.	2.2	2
5	Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100131.	1.1	4
6	A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients. <i>Journal of Thoracic Oncology</i> , 2020, 15, 80-90.	1.1	55
7	Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer. <i>Cancer</i> , 2020, 126, 373-380.	4.1	95
8	Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALK-Naive Patients With ALK-Rearranged NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 609-617.	1.1	27
9	Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies. <i>Cancer</i> , 2019, 125, 892-901.	4.1	117
10	Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies. <i>Future Oncology</i> , 2018, 14, 1477-1486.	2.4	14
11	Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials. <i>Clinical Lung Cancer</i> , 2018, 19, e465-e479.	2.6	56
12	Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1539-1548.	1.1	146
13	Clinical activity of ASP8273 in Asian patients with non-small cell lung cancer with EGFR activating and T790M mutations. <i>Cancer Science</i> , 2018, 109, 2852-2862.	3.9	15
14	Effect of postoperative systemic therapy on pulmonary adenocarcinoma with unexpected pleural spread detected during thoracotomy or thoracoscopy. <i>Oncotarget</i> , 2018, 9, 5435-5444.	1.8	6
15	First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. <i>Lancet</i> , 2017, 389, 917-929.	13.7	919
16	EGFR mutation, smoking, and gender in advanced lung adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 98384-98393.	1.8	58
17	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. <i>Lancet Oncology</i> , 2016, 17, 577-589.	10.7	950
18	Radiation recall pneumonitis induced by epidermal growth factor receptor-tyrosine kinase inhibitor in patients with advanced nonsmall-cell lung cancer. <i>Journal of the Chinese Medical Association</i> , 2016, 79, 248-255.	1.4	32

#	ARTICLE	IF	CITATIONS
19	First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Nonâ€“Small-cell Lung Cancer: Quality of Life Results From a Randomized Phase III Trial. <i>Clinical Lung Cancer</i> , 2016, 17, 150-160.	2.6	16
20	Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2016, 17, 1643-1652.	10.7	533
21	Effect of walking on circadian rhythms and sleep quality of patients with lung cancer: a randomised controlled trial. <i>British Journal of Cancer</i> , 2016, 115, 1304-1312.	6.4	62
22	First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Nonâ€“Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study. <i>Journal of Thoracic Oncology</i> , 2016, 11, 370-379.	1.1	21
23	Identifying cancer origin using circulating tumor cells. <i>Cancer Biology and Therapy</i> , 2016, 17, 430-438.	3.4	56
24	First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutationâ€“Positive Nonâ€“Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2016, 2, 305.	7.1	201
25	Phase 3 study of first-line crizotinib vs pemetrexedâˆ“cisplatin/carboplatin (PCC) in East Asian patients (pts) with <i>ALK</i>+ advanced non-squamous non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9058-9058.	1.6	7
26	Characteristics of young lung cancer: Analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking status. <i>Oncotarget</i> , 2016, 7, 46628-46635.	1.8	36
27	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations. <i>Journal of Thoracic Oncology</i> , 2015, 10, 793-799.	1.1	199
28	Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. <i>Lancet Oncology</i> , The, 2015, 16, 141-151.	10.7	1,369
29	ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naÃ“ve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8060-8060.	1.6	51
30	<i>MLH1</i>V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients with<i>EGFR</i>L858R-positive lung adenocarcinoma. <i>Oncotarget</i> , 2015, 6, 8407-8417.	1.8	17
31	Enhancement of tumor initiation and expression of KCNMA1, MORF4L2 and ASPM genes in the adenocarcinoma of lung xenograft after vorinostat treatment. <i>Oncotarget</i> , 2015, 6, 8663-8675.	1.8	14
32	Maintenance therapy with gefitinib (G)/pemetrexed (P) versus P alone after induction therapy with P/platinum for metastatic lung adenocarcinoma (MLADC) harboring no sensitizing epidermal growth factor receptor mutation (sEGFRm): A phase II multicenter randomized open-label study (GENIUS trial).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8043-8043.	1.6	0
33	Circulating free mitochondrial DNA concentration and its association with erlotinib treatment in patients with adenocarcinoma of the lung. <i>Oncology Letters</i> , 2014, 7, 2180-2184.	1.8	15
34	Physicianâ€“patient end-of-life care discussions: Correlates and associations with end-of-life care preferences of cancer patientsâ€“a cross-sectional survey study. <i>Palliative Medicine</i> , 2014, 28, 1222-1230.	3.1	42
35	Changes in symptom severity in Taiwanese lung cancer patients after gefitinib treatment: a pilot study. <i>International Journal of Palliative Nursing</i> , 2014, 20, 135-142.	0.5	2
36	A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Nonâ€“Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER). <i>Journal of Thoracic Oncology</i> , 2014, 9, 154-162.	1.1	1,131

#	ARTICLE	IF	CITATIONS
37	First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial. <i>European Journal of Cancer</i> , 2014, 50, 2219-2230.	2.8	44
38	Tivantinib plus erlotinib versus placebo plus erlotinib in Asian patients with previously treated nonsquamous NSCLC with wild-type EGFR: First report of a phase III ATTENTION trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8044-8044.	1.6	9
39	Analysis of treatment duration and safety of adjuvant erlotinib (E) versus placebo (P) after surgery in patients (pts) with non-small cell lung cancer (NSCLC): RADIANT trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7535-7535.	1.6	0
40	Combined epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and chemotherapy in non-small-cell lung cancer: Chemo-refractoriness of cells harboring sensitizing-EGFR mutations in the presence of gefitinib. <i>Lung Cancer</i> , 2013, 82, 305-312.	2.0	21
41	Gefitinib Enhances Cytotoxicities of Antimicrotubule Agents in Non-Small-Cell Lung Cancer Cells Exhibiting No Sensitizing Epidermal Growth Factor Receptor Mutation. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1218-1227.	1.1	20
42	Molecular epidemiological prospective study of EGFR mutations from Asian patients (pts) with advanced lung adenocarcinoma (PIONEER).. <i>Journal of Clinical Oncology</i> , 2012, 30, 1534-1534.	1.6	33
43	LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA7500-LBA7500.	1.6	74
44	ASPIRATION: Phase II study of continued erlotinib beyond RECIST progression in Asian patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS7614-TPS7614.	1.6	13
45	LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA7500-LBA7500.	1.6	60
46	Changing causes of death post-epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) era in patients with advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2012, 30, e18132-e18132.	1.6	0
47	Safety and Efficacy of First-Line Bevacizumab with Chemotherapy in Asian Patients with Advanced Nonsquamous NSCLC: Results from the Phase IV MO19390 (SAiL) Study. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1092-1097.	1.1	24
48	Antagonism between Gefitinib and Cisplatin in Non-small Cell Lung Cancer Cells: Why Randomized Trials Failed?. <i>Journal of Thoracic Oncology</i> , 2011, 6, 559-568.	1.1	32
49	Interrelationships between Cellular Nucleotide Excision Repair, Cisplatin Cytotoxicity, HER-2/neuGene Expression, and Epidermal Growth Factor Receptor Level in Non-small Cell Lung Cancer Cells. <i>Japanese Journal of Cancer Research</i> , 2000, 91, 213-222.	1.7	30
50	A Phase II Study of Single-agent Docetaxel Chemotherapy for Non-small Cell Lung Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2000, 30, 429-434.	1.3	17
51	Evaluation of the Relative Cytotoxic Effects of Anticancer Agents in Serum-supplemented versus Serum-free Media Using a Tetrazolium Colorimetric Assay. <i>Japanese Journal of Cancer Research</i> , 1996, 87, 91-97.	1.7	4
52	Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human lung cancer cell lines. <i>International Journal of Cancer</i> , 1990, 46, 101-105.	5.1	10